Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Safety Study of RSD1235 in Atrial Fibrillation
2005-004195-20Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vernakalant in Atrial fibrillation (AFib), sponsored by Astellas Pharma. Primary endpoint: Safety of RSD1235. Started Oct 2005; status: completed.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2005-004195-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004195-20.